Sanofi (SNY) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Sanofi  (NASDAQ: SNY)


Sanofi's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Sanofi's ROI in the fourth quarter of 2025?
Sanofi achieved a return on average invested assets (ROI) of 10.57 % in its fourth quarter of 2025, this is above SNY's average return on investment of 5.94%.
Sanofis investments during the 12 months ending in the fourth quarter of 2025 are valued at $83 billion

ROI has improved compared to 7.64% in the third quarter of 2025, due to net income growth.

Within the Healthcare sector 145 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2025 from to 1199.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Investment Change TTM -5.42 % -6.74 % -3.47 % -0.11 % 3.33 %
Y / Y Net Income Change TTM 39.75 % 3.35 % 3.35 % 3.35 % 3.35 %
Investment (TTM) in Millions 86,114 82,181 82,181 82,181 82,832
Return On Investment (TTM) 10.57 % 7.64 % 7.47 % 7.31 % 7.16 %
SNY's Overall Ranking # 1199 # # # # 1420
Seq. Investment Change TTM 1 % -2.21 % -2.16 % -2.12 % -0.42 %
Seq. Net Income Change TTM 39.75 % 0 % 0 % 0 % 3.35 %
Net Income (TTM) in Millions 8,793 6,292 6,292 6,292 6,292

SNY Company Profile >> Back to SNY Roi Comparisons >> See Annual SNY Return On Investment



Return On Investment SNY's Ranking
Within: No.
Industry # 57
Sector # 146
Overall # 1199

Return On Investment Statistics
High Average Low
9.45 %
5.94 %
3 %
(Dec 31 2020)   (Dec 31 2019)







Financial Statements
Sanofi's IV. Quarter Investments $ 86,114 Millions SNY's Balance sheet
Sanofi's IV. Quarter Income $ 8,793 Millions Quarterly SNY's Income Statement
SNY's Income by Division See SNY's Income by Division


SNY Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 86,114 82,832 84,304 82,367 136,090
Y / Y Investment Growth 3.96 % -1.75 % 2.35 % -39.48 % 20.6 %
Net Income in Millions 8,877 6,079 5,880 8,937 7,428
Y / Y Net Income Growth 46.03 % 3.38 % -34.21 % 20.31 % -47.29 %
Annual Return On Investment 10.31 % 7.34 % 6.97 % 10.85 % 5.46 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 10.31 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SNY's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SNY's Competitors
Subscribers only: Roi for Sanofi's Suppliers
Subscribers only: Return On Investment for SNY's Customers

Other Ratios
SNY's Roa SNY's Inventory Turnover Ratio SNY's Growth Rates SNY's Dividend Statistics
SNY's Profitability Ratios SNY's Asset Turnover Ratio SNY's Dividend Growth
SNY's Roe SNY's Valuation Ratios SNY's Financial Strength Ratios SNY's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector ROI
Adma Biologics Inc   28.75 %
Carlisle Companies Incorporated  27.24 %
Incyte Corporation  27.08 %
Vaxart Inc   26.63 %
Compugen Ltd  26.32 %
Arrowhead Pharmaceuticals Inc   25.56 %
Puma Biotechnology Inc   25.39 %
Catalyst Pharmaceuticals Inc   24.25 %
Iradimed Corporation  22.97 %
Innoviva Inc   22.62 %
Illumina Inc   22.37 %
Transmedics Group Inc   21.99 %
Zoetis Inc   21.25 %
Pro dex Inc   21.04 %
Dexcom Inc   20.78 %
Electromed Inc   20.50 %
Resmed Inc   20.35 %
Merck and Co Inc   20.17 %
Astrazeneca Plc  19.67 %
Vertex Pharmaceuticals Inc  19.48 %
Inspire Medical Systems inc   19.34 %
Mimedx Group Inc   19.27 %
Gilead Sciences Inc   19.26 %
United Therapeutics Corporation  18.71 %
Krystal Biotech Inc   18.51 %
Agilent Technologies inc   18.50 %
Chemed Corporation  18.05 %
Hca Healthcare Inc   17.95 %
Sbc Medical Group Holdings Incorporated  17.85 %
Lifevantage Corp  17.77 %

Date modified: 2026-06-24T10:07:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.